New HIV drugs should be classed as inferior if they carry a higher risk of resistance
Dolutegravir resistance is rare, but some risk factors can up the odds
UK experts recommend statins for all people with HIV aged 40 and over
Is on-demand PrEP too demanding? Australian men’s experiences
New weight-loss drugs appear safe and effective for people living with HIV
More evidence that integrase inhibitors don’t raise heart disease risk
CRISPR gene therapy appears safe, but claims of an imminent HIV cure are premature
Long-acting injectable treatment highly effective in European cohort studies
Body mass index is sufficient to predict diabetes or metabolic syndrome, Italian study finds
